Zobrazeno 1 - 10
of 144
pro vyhledávání: '"Velden, W.J.F.M."'
Autor:
Rijneveld, A.W., Holt, B. van der, Weerdt, O. de, Biemond, B.J., Loosdrecht, A.A. van de, Wagen, L.E. van der, Bellido, M., Gelder, M. van, Velden, W.J.F.M. van der, Selleslag, D., Lammeren-Venema, D. van, Halkes, C.J.M., Fijnheer, R., Havelange, V., Sluis, G.L. van, Legdeur, M.C., Deeren, D., Gadisseur, A., Sinnige, H.A.M., Breems, D.A., Jaspers, A., Legrand, O., Terpstra, W.E., Boersma, R.S., Mazure, D., Triffet, A., Tick, L.W., Beel, K., Maertens, J.A., Beverloo, H.B., Bakkus, M., Homburg, C.H.E., Haas, V. de, Velden, V.H.J. van der, Cornelissen, J.J., Dutch-Belgian HOVON Cooperative Gr
Publikováno v:
Blood advances, 6(4). The American Society of Hematology
Blood advances, Vol. 6, no.4, p. 1115-1125 (2022)
Blood advances, 6(4), 1115-1125. American Society of Hematology
Blood Advances, 6, 4, pp. 1115-1125
Blood Advances, 6, 1115-1125
Blood Advances, 6(4), 1115-1125. ELSEVIER
Blood advances
BLOOD ADVANCES
Blood, 6(4), 1115-1125. AMER SOC HEMATOLOGY
Blood advances, Vol. 6, no.4, p. 1115-1125 (2022)
Blood advances, 6(4), 1115-1125. American Society of Hematology
Blood Advances, 6, 4, pp. 1115-1125
Blood Advances, 6, 1115-1125
Blood Advances, 6(4), 1115-1125. ELSEVIER
Blood advances
BLOOD ADVANCES
Blood, 6(4), 1115-1125. AMER SOC HEMATOLOGY
Clofarabine (CLO) is a nucleoside analog with efficacy in relapsed/refractory acute lymphoblastic leukemia (ALL). This randomized phase 3 study aimed to evaluate whether CLO added to induction and whether consolidation would improve outcome in adults
Publikováno v:
Nederlands Tijdschrift voor Hematologie, 20, 4, pp. 180-2
Item does not contain fulltext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1236::35b3e8ae7cd1ff4925675548cab6b9b3
https://repository.ubn.ru.nl/handle/2066/294564
https://repository.ubn.ru.nl/handle/2066/294564
Autor:
Cruijsen, M.1 (AUTHOR), van der Velden, W.J.F.M1 (AUTHOR), de Haan, A.F.J.2 (AUTHOR), Klein, S. K.3 (AUTHOR), Hoogendoorn, M.4 (AUTHOR), Tromp, Y.5 (AUTHOR), de Valk, B.6 (AUTHOR), van Rees, B.7 (AUTHOR), de Boer, F.8 (AUTHOR), van der Spek, E.9 (AUTHOR), Pruijt, J.10 (AUTHOR), Verdonck, L.F.11 (AUTHOR), Vellenga, E.12 (AUTHOR), Blijlevens, N.1 (AUTHOR), van de Loosdrecht, A. A.13 (AUTHOR), Huls, G.12 (AUTHOR)
Publikováno v:
Leukemia & Lymphoma. Nov2020, Vol. 61 Issue 11, p2752-2755. 4p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Bosch, M., Langemeijer, S.M.C., Velden, W.J.F.M. van der, Blijlevens, N.M.A., Groningen, L.F.J. van
Publikováno v:
Nederlands Tijdschrift voor Hematologie, 18, 35-41
Nederlands Tijdschrift voor Hematologie, 18, 1, pp. 35-41
Nederlands Tijdschrift voor Hematologie, 18, 1, pp. 35-41
Item does not contain fulltext
Autor:
Ossenkoppele, G.J., Breems, D.A., Stuessi, G., Norden, Y. van, Bargetzi, M., Biemond, B.J., Borne, P.A. von dem, Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., Janssen, J.J.J.W., Jaspers, A., Jongen-Lavrencic, M., Jongh, E. de, Klein, S.K., Klift, M. van der, Kooy, M.V., Maertens, J., Micheaux, L., Poel, M.W.M. van der, Rhenen, A. van, Tick, L., Valk, P., Vekemans, M.C., Velden, W.J.F.M. van der, Weerdt, O. de, Pabst, T., Manz, M., Lowenberg, B., Havelange, Moors, I., Obberg, F. van, Maertens, J.A., Hodossy, B., Vansteenweghen, S., Lammertijn, L., Sonet, A., Triffet, A., Gjertsen, B.T., Passweg, J., Heim, D., Giovanni, S., Betticher, D., Spertini, O., Gregor, M., Hess, U., Manz, M.G., Loosdrecht, A. van de, Janssen, J.J.W.M., Esser, J.W.J. van, Brouwer, R.E., Lammeren-Venema, D. van, Levin, M.D., Tick, L.W., Legdeur, M.C.J.C., Vellenga, E., Hoogendoorn, M., Veelken, J.H., Schouten, H.C., Cornelissen, J., Wouters, B., Raaijmakers, H.G.M., Kuball, J., Dutch-Belgian Hemato-Oncology, Swiss Grp Clinical Canc Res SAKK
Publikováno v:
Leukemia, 1751-1759. Nature Publishing Group
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
ISSUE=7;STARTPAGE=1751;ENDPAGE=1759;ISSN=0887-6924;TITLE=Leukemia
Leukemia, 34(7), 1751-1759. Nature Publishing Group
Leukemia, 34, 7, pp. 1751-1759
Ossenkoppele, G J, Breems, D A, Stuessi, G, van Norden, Y, Bargetzi, M, Biemond, B J, A von dem Borne, P, Chalandon, Y, Cloos, J, Deeren, D, Fehr, M, Gjertsen, B T, Graux, C, Huls, G, Janssen, J J J W, Jaspers, A, Jongen-Lavrencic, M, de Jongh, E, Klein, S K, Van der Klift, M, Van Marwijk Kooy, M, Maertens, J, Micheaux, L, van der Poel, M W M, Van Rhenen, A, Tick, L, Valk, P, Vekemans, M C, van der Velden, W J F M, de Weerdt, O, Pabst, T, Manz, M, Löwenberg, B & for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) 2020, ' Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS ', Leukemia, vol. 34, no. 7, pp. 1751-1759 . https://doi.org/10.1038/s41375-020-0725-0
Leukemia, 34, 1751-1759. NATURE PUBLISHING GROUP
Leukemia, 34, 1751-1759
Leukemia, Vol. 34, no. 7, p. 1751-1759 (2020)
Contains fulltext : 225470.pdf (Publisher’s version ) (Closed access) More effective treatment modalities are urgently needed in patients with acute myeloid leukemia (AML) of older age. We hypothesized that adding lenalidomide to intensive standard
Publikováno v:
Frontiers in Immunology, 13
BackgroundSystemic sclerosis (SSc) is a complex autoimmune disease characterized by inflammation, vasculopathy and fibrosis of the skin and internal organs. Treatment with autologous hematopoietic cell transplantation (HCT) for progressive SSc has im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cad6217f75b0224cccc0e681ba6fd47
https://doi.org/10.3389/fimmu.2022.925776
https://doi.org/10.3389/fimmu.2022.925776
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.